- Clinical stage biotechnology company Replimune Group (NASDAQ:REPL) priced its public offering of ~6.92M shares at a public offering price of $13.00 per share.
- Gross proceeds are expected to be approximately $140M.
- Underwriters have a 30-day option to purchase up to an additional ~1.62M shares.
- The offering is expected to close on November 27, 2024.
Replimune prices $140M offering at $13 per share (NASDAQ:REPL)
BlackSky announces proposed public offering of common stock
